Curacyte and IBFB Pharma annouce merger
Curacyte AG has announced its merger with IBFB PHARMA GmbH. Curacyte AG will remain a financial holding with three wholly owned operating subsidiaries in Leipzig, Jena (Germany) and Chapel Hill, NC (USA) employing approximately 50 staff. The combined company"s headquarters will relocate from Munich to Leipzig.
In addition, Curacyte announced the successful completion of a EUR16.5 ($21.6) million Series C private placement. This financing round will support the development of the company"s combined product portfolio. Terms of the merger and Series C Financing transaction were not disclosed.
The merger creates a biopharmaceutical company with a rich clinical, pre-clinical and discovery pipeline of medicines to treat inflammatory and cardiovascular diseases. Curacyte"s lead product, PHP, is in phase 3 clinical development for distributive shock and phase 1 as a concomitant treatment for interleukin-2 (IL-2) treated patients with renal cell carcinoma and metastatic melanoma. Supported by encouraging results from a recent Phase 2c clinical trial of PHP in distributive shock, Curacyte is currently in discussions with potential pharmaceutical partners who have the ability to develop and market the product. The combined company has several pre-clinical products, scheduled to enter clinical development in 2006. Apart from establishing therapeutic focus, IBFB complements Curacyte's research resulting in leading edge drug discovery operations.
Most read news
Organizations
Other news from the department business & finance

Get the life science industry in your inbox
By submitting this form you agree that LUMITOS AG will send you the newsletter(s) selected above by email. Your data will not be passed on to third parties. Your data will be stored and processed in accordance with our data protection regulations. LUMITOS may contact you by email for the purpose of advertising or market and opinion surveys. You can revoke your consent at any time without giving reasons to LUMITOS AG, Ernst-Augustin-Str. 2, 12489 Berlin, Germany or by e-mail at revoke@lumitos.com with effect for the future. In addition, each email contains a link to unsubscribe from the corresponding newsletter.